Aim of the Project:
ARTemis is a phase III, randomised trial to determine whether the addition to neo-adjuvant chemotherapy of an anti-angiogenic agent bevacizumab is more effective than standard chemotherapy alone in terms of short-term and long-term outcome in women presenting with HER2-negative early breast cancer.
Associated translational science will use prospective molecular profiling and candidate gene analysis on paraffin embedded and fresh tissue to define molecular predictors response / resistance to bevacizumab and chemotherapy. A quality of life sub-study will collect data critical to any future health technology assessment of bevacizumab in this indication.
South East Research Ethics Committee
Start date: April 2009. Closed to recruitment: 09 January 2013. 800 patients recruited.
Joint sponsorship - University of Cambridge and Cambridge University Hospitals NHS Foundation Trust
|Dr Jean Abraham - Cambridge
|Dr Larry Hayward - Edinburgh
|Deputy Chief Investigator
|Professor Janet Dunn - Warwick